The US Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 vector-based gene therapy, for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain gene.
[FDA]
